Jessy D. Dorn

Learn More
PURPOSE This study evaluated the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, CA) in blind subjects with severe outer retinal degeneration. DESIGN Single-arm, prospective, multicenter clinical trial. PARTICIPANTS Thirty subjects were enrolled in the United States and Europe between June 6, 2007, and August 11, 2009.(More)
BACKGROUND/AIMS To determine to what extent subjects implanted with the Argus II retinal prosthesis can improve performance compared with residual native vision in a spatial-motor task. METHODS High-contrast square stimuli (5.85 cm sides) were displayed in random locations on a 19″ (48.3 cm) touch screen monitor located 12″ (30.5 cm) in front of the(More)
The Argus II Retinal Prosthesis System is the only commercially-approved treatment for severe to profound Retinitis Pigmentosa in the world. Over 10 years of research and development have gone into this device; it is now commercially available in the European Economic Area, Saudi Arabia, and in the United States. The Argus II System consists of an implant(More)
The Argus II 60 channel epiretinal prosthesis has been developed in order to provide partial restoration of vision to subjects blinded from outer retinal degenerative disease. To date the device has been implanted in 21 subjects as part of a feasibility study. In 6 month post-implantation door finding and line tracking orientation and mobility testing,(More)
PURPOSE Retinitis pigmentosa (RP) is a group of inherited retinal degenerations leading to blindness due to photoreceptor loss. Retinitis pigmentosa is a rare disease, affecting only approximately 100 000 people in the United States. There is no cure and no approved medical therapy to slow or reverse RP. The purpose of this clinical trial was to evaluate(More)
The cross-correlation coefficient between neural spike trains is a commonly used tool in the study of neural interactions. Two well-known complications that arise in its interpretation are 1) modulations in the correlation coefficient may result solely from changes in the mean firing rate of the cells and 2) the mean firing rates of the neurons impose upper(More)
OBJECTIVE To investigate the ability of 28 blind subjects implanted with a 60-electrode Argus II (Second Sight Medical Products Inc) retinal prosthesis system to detect the direction of a moving object. METHODS Blind subjects (bare light perception or worse in both eyes) with retinitis pigmentosa were implanted with the Argus II prosthesis as part of a(More)
OBJECTIVE To demonstrate that an epiretinal prosthesis can produce patterned visual perception in patients blinded by photoreceptor degeneration who have no other treatment options. METHODS A totally blind subject with retinitis pigmentosa had a 16-electrode epiretinal prosthesis implanted. The implant is controlled wirelessly by an external computer or a(More)
BACKGROUND Retinal prosthesis systems (RPS) are a novel treatment for profound vision loss in outer retinal dystrophies. Ideal prostheses would offer stable, long-term retinal stimulation and reproducible spatial resolution in a portable form appropriate for daily life. METHODS We report a prospective, internally controlled, multicentre trial of the Argus(More)
BACKGROUND Research groups and funding agencies need a functional assessment suitable for an ultra-low vision population to evaluate the impact of new vision-restoration treatments. The purpose of this study was to develop a pilot assessment to capture the functional visual ability and well-being of subjects whose vision has been partially restored with the(More)